Pancreatic Cancer Research

ResearcherUniversité Libre de BruxellesActive in the last 2 years

Christelle Bouchart

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1714-234X; OpenAlex author ID A5003699726. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 5, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 6 papers, 1 trial · 2024: 6 papers · 2025: 3 papers · 2026: 5 papers

Papers 26

  1. Evaluation of loco-regional recurrences using deformable image registration after isotoxic high dose stereotactic body radiotherapy in localised pancreatic can… Last author DOI 10.1016/j.ctro.2025.101081↗
  2. Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC survey. Co-author DOI 10.1016/j.esmogo.2026.100372↗
  3. From contouring variability to dosimetric impact: a comprehensive assessment of online adaptive MR-guided SBRT for pancreatic cancer. Last author DOI 10.1016/j.radonc.2026.111834↗
  4. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy. Co-author DOI 10.1038/s41416-025-03274-0↗
  5. Suicide Risk and Associated Factors in Patients with Pancreatic Cancer: A Systematic Review. First author DOI 10.3390/diseases14090346↗
  6. Glycation Stress–Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer Co-author DOI 10.1101/2025.07.07.663493↗
  7. Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO). Co-author DOI 10.1186/s12885-025-15041-8↗
  8. Impact of Depression on Mortality in Patients with Pancreatic Cancer: A Systematic Review. First author DOI 10.3390/curroncol32090511↗
  9. High-resolution and quantitative spatial analysis reveal intra-ductal phenotypic and functional diversification in pancreatic cancer. Co-author DOI 10.1002/path.6212↗
  10. Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: "Pancreat… First author DOI 10.1016/j.annonc.2024.05.003↗
  11. Impact of the radiological morphology of the mesopancreas on the outcome after pancreatoduodenectomy for pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrae134↗
  12. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Stereotactic Body Radiotherapy Co-author DOI 10.1101/2024.04.30.591890↗
  13. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging. Co-author DOI 10.3390/biomedicines12030591↗
  14. Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better? Co-author DOI 10.3390/cancers16132423↗
  15. Neoadjuvant chemotherapy associated with isotoxic high-dose stereotactic body radiotherapy does not increase postoperative complications after pancreaticoduode… First author DOI 10.1002/jso.27252↗
  16. Peritoneal patch in vascular reconstruction during pancreaticoduodenectomy for pancreatic cancer: a single Centre experience. Co-author DOI 10.1080/00015458.2021.1979173↗
  17. No evidence for the presence and control of tumor growth by cytoplasmic stress granules in pancreatic cancer Co-author DOI 10.1101/2023.11.13.566518↗
  18. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline rese… Co-author DOI 10.1186/s12885-023-11327-x↗
  19. Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to B… Last author DOI 10.3390/cancers15030768↗
  20. A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells13010003↗
  21. Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Eval… Last author DOI 10.3390/cancers14235730↗
  22. EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score. Co-author DOI 10.1055/a-1324-2892↗
  23. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenoc… Co-author DOI 10.1177/17588359211045860↗
  24. What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact? First author DOI 10.1245/s10434-020-09568-2↗
  25. Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind. Co-author DOI 10.3390/cancers13061231↗
  26. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Co-author DOI 10.1177/1758835920936093↗

Trials 1

  1. Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma Principal investigator NCT05083247↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Luc Van Laethem · 19 shared papers, 1 shared trial, 2020–2026 · strength 4.17
  2. Julie Navez · 15 shared papers, 2020–2026 · strength 2.76
  3. Tatjana Arsenijevic · 10 shared papers, 2021–2026 · strength 1.91
  4. Matthieu Hein · 6 shared papers, 2021–2026 · strength 1.68
  5. Jean Closset · 8 shared papers, 2020–2024 · strength 1.30
  6. Oier Azurmendi Senar · 6 shared papers, 2023–2026 · strength 1.19
  7. Pieter Demetter · 6 shared papers, 2021–2026 · strength 1.09
  8. Kosta Stosic · 5 shared papers, 2023–2026 · strength 1.00
  9. Rémy Nicolle · 5 shared papers, 2021–2026 · strength 0.89
  10. Nicky D’Haene · 5 shared papers, 2021–2026 · strength 0.89
  11. Maria Antonietta Bali · 5 shared papers, 2021–2024 · strength 0.79
  12. Sara Poeta · 2 shared papers, 2026 · strength 0.66
  13. F. Huguet · 2 shared papers, 2024–2026 · strength 0.56
  14. Ilse Rooman · 3 shared papers, 2024–2026 · strength 0.55
  15. Martin Manderlier · 2 shared papers, 2022–2026 · strength 0.51
  16. Maxence Chicoisneau · 1 shared paper, 2026 · strength 0.50
  17. Rita Saúde-Conde · 2 shared papers, 2024 · strength 0.50
  18. Ellis Michiels · 2 shared papers, 2024–2026 · strength 0.39
  19. Léo Mas · 2 shared papers, 2024–2026 · strength 0.38
  20. Shulin Zhao · 2 shared papers, 2024–2026 · strength 0.38
  21. Jean‐Baptiste Bachet · 2 shared papers, 2024–2026 · strength 0.38
  22. Timon Vandamme · 2 shared papers, 2023–2025 · strength 0.37
  23. Marie-Lucie Racu · 2 shared papers, 2023–2024 · strength 0.37
  24. Cindy Neuzillet · 1 shared paper, 2026 · strength 0.36
  25. Matthieu Delaye · 1 shared paper, 2026 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.